MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]

Aaron T. Gerds, Srđan Verstovšek, Alessandro M. Vannucchi, Haifa Kathrin Al‐Ali, David Lavie, Andrew Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela Lazaroiu, Miklós Egyed, María Laura Fox, Donal P. McLornan, Andrew C. Perkins, Sung‐Soo Yoon, Vikas Gupta, Jean‐Jacques Kiladjian, Rafe Donahue, Jun Kawashima, Ruben A. Mesa
In: Clinical Lymphoma Myeloma and Leukemia · 2022 · vol. 22 , pp. S340 · doi:10.1016/s2152-2650(22)01464-1 · W4296468477
OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by qwen3.7-flash, 2026-10-02 ⓘ

The MOMENTUM phase 3 randomized trial compared momelotinib versus danazol in thrombocytopenic myelofibrosis patients previously treated with a JAK inhibitor.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-11T04:20:12.799902+00:00
unpaywall
last seen: 2026-11-03T06:29:01.780496+00:00
License: CC0 · commercial use OK